Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 32 citing articles:

Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial
Jianchao Xu, Jinzhong Song, Ziyu Xie, et al.
Medicine (2023) Vol. 102, Iss. 51, pp. e36714-e36714
Open Access | Times Cited: 26
A Multi-Center Study Investigating Long COVID-19 in Healthcare Workers from North-Eastern Italy: Prevalence, Risk Factors and the Impact of Pre-Existing Humoral Immunity—ORCHESTRA Project
Luca Cegolon, Marcella Mauro, Donatella Sansone, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1769-1769
Open Access | Times Cited: 23
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 6
Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study
Weijie Wang, Yu‐Hsun Wang, Ching‐Hua Huang, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
COVID-19 in City Council Civil Servants, 1 March 2020–31 January 2023: Risk of Infection, Reinfection, Vaccine Effectiveness and the Impact of Heterologous Triple Vaccination
Luca Cegolon, Francesca Larese Filon
Vaccines (2024) Vol. 12, Iss. 3, pp. 254-254
Open Access | Times Cited: 2
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2119-2131
Open Access | Times Cited: 2
Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study
Andrea De Vito, Giulia Moi, Laura Saderi, et al.
Viruses (2023) Vol. 15, Iss. 11, pp. 2180-2180
Open Access | Times Cited: 7
Predictors of COVID-19 Severity in Elderly Patients Infected by Omicron in China, 18 December 2022–5 February 2023
Y. Xing, Yupeng Li, Liting Feng, et al.
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 4505-4518
Open Access | Times Cited: 5
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
Sydney Paltra, Tim Conrad
Advances in respiratory medicine (2024) Vol. 92, Iss. 1, pp. 66-76
Open Access | Times Cited: 1
Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID‐19
Li‐Chen Chang, I‐Wen Chen, Kuo‐Chuan Hung
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Closed Access | Times Cited: 1
Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis
Bahman Amani, Behnam Amani
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 1
Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir
Francesca Bai, Tomaso Beringheli, Virginia Vitaletti, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 7, pp. 1589-1605
Open Access | Times Cited: 1
Effect of Maraviroc and/or Favipiravir plus systemic steroids versus systemic steroids only on the viral load of adults with severe COVID-19: clinical trial
Elba Medina, Ana Laura Sánchez-Sandoval, Eira Valeria Barrón-Palma, et al.
F1000Research (2024) Vol. 13, pp. 180-180
Open Access | Times Cited: 1
Exploring early COVID-19 therapies, variants, and viral clearance dynamics: Insights from a high-risk outpatients study
Marta Colaneri, Maddalena Matone, Federico Fassio, et al.
Diagnostic Microbiology and Infectious Disease (2024) Vol. 110, Iss. 2, pp. 116452-116452
Open Access | Times Cited: 1
Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, et al.
Infectious Disease Reports (2023) Vol. 15, Iss. 6, pp. 662-678
Open Access | Times Cited: 4
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study
Matteo Rinaldi, Caterina Campoli, Mena Gallo, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
Henrik Berg Rasmussen, Peter Riis Hansen
Viruses (2023) Vol. 15, Iss. 11, pp. 2151-2151
Open Access | Times Cited: 2
Impact of Using Antiviral Therapy on COVID-19 Progression in ICU Patients: A Saudi Arabian Retrospective Analysis
Lama Tariq Alkhunaizi, Jawza Ali Almutairi, Sarah Hamad Almanea, et al.
Cureus (2024)
Open Access
Retrospective Cohort Study on Determinants of Mechanical Ventilation Duration of COVID-19 ICU Patients
Khalid Jameel Alsuwat, Yasseer Youssef Sonbul, Khalid Al Harbi, et al.
Cureus (2024)
Open Access
Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study
Liang Xu, Xiu xiu Chen, Xuying Yang, et al.
Research Square (Research Square) (2024)
Open Access
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
Behnam Amani, Bahman Amani
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 7, pp. 547-555
Closed Access
Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China
Wei Yang, Yahui Peng, Changsong Wang, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 1267-1279
Open Access
Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
Yi Zhang, Xinrui Wang, Chong Huang, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 1367-1377
Open Access
Exploring Early Covid-19 Therapies, Variants, and Viral Clearance Dynamics: Insights from a High-Risk Outpatients Study
Maddalena Matone, Marta Colaneri, Federico Fassio, et al.
(2024)
Open Access
Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression
Adeel A. Butt, Peng Yan, Obaid S. Shaikh
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0298254-e0298254
Open Access
Page 1 - Next Page

Scroll to top